Clinical Trial Update: Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SGS-742 in succinic semialdehyde dehydrogenase deficiency has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Disease
• Seizures

Drugs mentioned

• SGS-742 (SGS-742)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Metabolic Disease, Seizures | Phase 2 | Status: COMPLETED | Results posted: 2020-02-24